Chimerix, Inc. (NASDAQ:CMRX) Insider Sells $13,792.50 in Stock

Chimerix, Inc. (NASDAQ:CMRX) insider Allen S. Melemed sold 3,065 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $4.50, for a total value of $13,792.50. Following the completion of the transaction, the insider now directly owns 152,875 shares of the company’s stock, valued at approximately $687,937.50. This trade represents a 1.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Chimerix Trading Down 3.9 %

NASDAQ CMRX opened at $4.38 on Monday. The stock has a market capitalization of $393.94 million, a price-to-earnings ratio of -4.66 and a beta of 0.35. Chimerix, Inc. has a twelve month low of $0.75 and a twelve month high of $4.65. The stock has a 50-day moving average of $3.53 and a 200 day moving average of $1.83.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on CMRX shares. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Chimerix in a report on Monday, December 30th. Wedbush reissued an “outperform” rating and issued a $6.00 price objective on shares of Chimerix in a report on Tuesday, December 10th.

Hedge Funds Weigh In On Chimerix

A number of large investors have recently bought and sold shares of the business. Bender Robert & Associates purchased a new stake in Chimerix during the 4th quarter worth approximately $37,000. Susquehanna Fundamental Investments LLC purchased a new stake in Chimerix during the 4th quarter worth approximately $59,000. Jane Street Group LLC purchased a new stake in Chimerix during the 4th quarter worth approximately $62,000. Diadema Partners LP purchased a new stake in Chimerix during the 4th quarter worth approximately $101,000. Finally, Stoneridge Investment Partners LLC increased its stake in Chimerix by 22.5% during the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 8,134 shares in the last quarter. Institutional investors and hedge funds own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.